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Muscular dystrophyWild type and dystrophic (merosin-deﬁcient) Lama2dy mice muscles were compared for their density of
lipid rafts. The 5-fold higher level of caveolin-3 and the 2-3 times higher level of ecto-5’-nucleotidase
activity in raft preparations (Triton X-100-resistant membranes) of dystrophic muscle supported
expansion of caveolar and non-caveolar lipid rafts. The presence in rafts of glycosylphosphatidylinositol
(GPI)-linked acetylcholinesterase (AChE) dimers, which did not arise from erythrocyte or nerve, not only
revealed for the ﬁrst time the capacity of the myoﬁbre for translating the AChE-H mRNA but also an
unrecognized pathway for targeting AChE-H to specialized membrane domains of the sarcolemma. Rafts of
dystrophic muscle contained a 5-fold higher AChE activity/mg protein. RT-PCR for 3’-alternative mRNAs of
AChE revealed AChE-T mRNA prevailing over AChE-R and AChE-H mRNAs in wild type mouse muscle. It
also displayed principal 5’-alternative AChE mRNAs with exons E1c and E1e (the latter coding for N-
terminally extended subunits) and fewer with E1d, E1a and E1b. The levels of AChE and butyrylcholi-
nesterase mRNAs were unaffected by dystrophy. Finally, the decreased level of proline-rich membrane
anchor (PRiMA) mRNA in Lama2dy muscle provided for a rational explanation to the loss of PRiMA-
bearing AChE tetramers in dystrophic muscle.ica y Biología Molecular-A,
21, E-30071 Espinardo, Murcia,
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Nearly half of patients (30-40%) suffering from congenital muscular
dystrophy (CMD) shows a deﬁciency of the laminin-α2 chain (called
merosin). Thus, the term ‘merosin-deﬁcient CMD’ (MCMD) applies to
the disease arising from anomalies in the LAMA2 gene that encodes
merosin [1,2]. LAMA2 mutations affect laminin-2 (α2β1γ1) and
laminin-4 (α2β2γ1). At the extracellular matrix laminin-2 links the
sarcolemma through integrin α7β1D and α-dystroglycan, a protein of
the dystrophin-glycoprotein complex that spanning the sarcolemma
joins the extracellular matrix with the cytoskeleton of the myoﬁbre.
Laminin-2 is needed to seal the sarcolemma with the basement
membrane. Its absence renders the sarcolemma fragile and permeable
to calcium, and its increase leads to myoﬁbre damage and muscle
wasting [1,2]. Despite the above, the molecular etiopathogenesis of
MCMD remains unsolved due to the variety of functions played by
laminin-2. In humans and mice, MCMD leads to muscle degeneration
and nerve dysmyelination [3], and, although several mouse strains
(Lama2dy, dy2j, dyw, and dy3k) are used for unveiling laminin-2functions, the deﬁciency of merosin makes it the Lama2dy mouse a
suitable model for MCMD studies [1].
Lipid rafts are membrane domains rich in cholesterol, sphingoli-
pids and speciﬁc proteins, which have been shown to be involved in
signal transduction [4]. The rafts are surrounded by less organized
lipid/protein mixtures referred to as non-raft membranes [5,6].
Caveolae, the omega-shaped invaginations of the plasma membrane,
are particular lipid rafts that contain the scaffolding protein caveolin
(Cav) [7]; non-caveolar rafts are devoid of caveolin.
Acetylcholinesterase (AChE; EC 3.1.1.7) regulates synaptic and
neurohumoral cholinergic activity by hydrolysing acetylcholine. Both
5’ and 3’-alternatively spliced AChEmRNA variants have been identiﬁed
[8,9]. 3’ spliced mRNAs generate the three classical AChE catalytic
subunits, T, H and R [8,10]. AChE-T is by far the major and the most
physiologically relevant subunit in mammalian brain and muscle. In
muscle, AChE-T polymerizes into globular (G1, G2 and G4) and
asymmetric (A4, A8 and A12) forms, which, after appropriate processing,
reach speciﬁc cell stores [11,12]. The asymmetric species are the
principal if not the only AChE forms in the neuromuscular junction
(NMJ) of fast-twitch muscle [13]. The AChE-R subunit can replace the
AChE-T protein in the oligomers of brain [8] and the AChE-H subunit
incorporates glycosylphosphatidylinositol (GPI) and generates GPI-
anchored G1 and G2 species [14]. Though functionally unrelated, AChE
and ecto-5’-nucleotidase (eNT; CD73) share some properties. Both
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where they hydrolyse neurotransmitters (acetylcholine and AMP) [15].
The importance of lipid rafts for membrane trafﬁc [6] besides the
increased number of caveolae in muscle of dystrophin-deﬁcient mice
[16] and of patients with Duchenne muscular dystrophy [17]
prompted us to study ﬁrstly whether the merosin deﬁciency affected
or not the population of lipid rafts in muscle. Moreover, bearing in
mind: 1) the incorporation of GPI-linked proteins in lipid rafts [5]; 2)
the presence in tissues of GPI-linked AChE-H protein; and 3) the role
of rafts in targeting nicotinic receptors (nAChR) to the NMJ [18], our
second goal was to look at the possible sorting of GPI-anchored AChE
to lipid rafts as a means to justify the presence of AChE-H mRNA and
protein in muscle and other tissues. Besides, given the abnormal
pattern of AChE forms in merosin-deﬁcient muscle [11] and the
capacity of AChE to bind laminin, caveolin and other protein partners
[19–21] it might be that the merosin deﬁciency disrupted AChE
transport toward the surface membrane of muscle.
Since both caveolar and non-caveolar rafts exist, our third
objective was to explore whether the content of non-caveolar rafts
increased in merosin-deﬁcient muscle. For this, advantage of the
widely accepted use of catalytically active eNT as a marker of non-
caveolar rafts was taken [22,23]. Some of the results reported here
have been published in a preliminary form [24].
2. Methods
2.1. Materials
Acetylthiocholine and butyrylthiocholine iodide, 5,5'-dithio-bis-
2-nitrobenzoic acid, tetraisopropyl pyrophosphoramide (Iso-
OMPA), 1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one
dibromide (BW284c51), AMP, α,β-methylene-ADP, Fiske-Subbarow
reagent, 2-(N-morpholino)ethanesulfonic acid (MES), antiprotei-
nases, polyoxyethylene10-oleyl ether (Brij 96), sedimentation anal-
ysis markers (beef liver catalase, 11.4 S, and alkaline phosphatase,
6.1 S), Triton X-100, agarose-bound plant lectins, nitrocellulose
membranes, peroxidase-conjugated anti-rabbit IgG (mAb A1949),
anti-mouse IgG (pAb A9917) and anti-goat IgG (mAb A9452) were
all provided by Sigma. Phosphatidylinositol-speciﬁc phospholipase C
(PIPLC) from B. thuringiensis was kindly donated by Dr. Nigel M.
Hooper (Univ. Leeds, UK). Primers for amplifying selected mRNAs
were purchased from Invitrogen (Carlsbad CA, USA) and a PCR
Master Mix from Applied Biosystems (Foster City CA, USA). The
antibodies anti-Cav3 (mAb 610420) and anti-human AChE (mAb
610267) were from BD Biosciences (San Jose CA, USA). The rabbit
antiserum against eNT of beef was a gift from Carlo Fini (Univ.
Perugia, Italy). Alexa Fluor 488 goat anti-mouse IgG (pAb A11001)
was from Molecular Probes (Eugene OR, USA). Western blots were
developed by using the ECL Plus kit of Amersham Biosciences
(Buckinghamshire, UK).
2.2. Isolation of lipid rafts
Breeding pairs of phenotypically normal (Lama2 +/?) and
dystrophic (Lama2 dy/dy; dystrophin-positive, merosin-negative)
129B6F1/J mice were purchased from Jackson Labs. (Bar Harbor, ME,
USA). Mice were kept and bred in the animal care unit of the
University of Murcia and handled according to the Spanish legislation
on ‘Protection of Animals’ and the Directives of the European
Community. Lipid rafts of normal (NM) and dystrophic mouse muscle
(DM) were isolated by their buoyancy in sucrose gradients essentially
as reported elsewhere [25]. Normal and dystrophic mice, three
months old and without sex distinction, were deeply anaesthetised
with ether before heart perfusion with 5.4 mM EDTA, 154 mM NaCl,
pH 7.4. Then, the hind limb muscles were excised and homogenized
(20%w/v) inMES-buffered saline (MBS; 150 mMNaCl in 25 mMMES,pH 6.5) supplemented with 1% Triton X-100 and a cocktail of
antiproteinases made of bacitracin (1 mg/ml), benzamidine (2 mM),
pepstatin A (10 μg/ml), leupeptin (20 μg/ml), aprotinin (20 U/ml)
and soybean trypsin inhibitor (0.1 mg/ml). The muscle was ground in
Ultra-Turrax at low speed, ﬁve times for 10 s with 40 s intervals, and
then in a glass-glass Potter (10 strokes). After centrifugation at 4 °C
(5 min at 1,000×g) the supernatant wasmixedwith its volume of 80%
sucrose in MBS. The mixture (4 ml) was placed on centrifuge tubes
and, after adding a 30-5% continuous sucrose gradient over the
mixture, the tubes were centrifuged at 165,000×g, for 16-20 h at 4 °C,
in a SW41 Beckman rotor. Twelve fractions of 1 ml were collected
from the top of the gradient and the Triton-resistant membrane
fractions, containing the lipid rafts, were identiﬁed by their content in
the protein markers of caveolar or non-caveolar rafts, i.e., Cav3 and
eNT activity. More than 95% of the protein remained within the 40%
sucrose layer, which contained the Triton X-100-soluble membranes.
Fourteen raft preparations of NM and twelve of DM were analyzed.
2.3. Western blot analysis
Possible variation between NM and DM in the content of the raft
markers Cav3 and eNT was assessed by Western blot. The presence of
AChE in rafts was also tested. For this, 10 μg of protein of each gradient
fraction was subjected to SDS-PAGE in 7.5% or 12.5% polyacrylamide
gel slabs [26]. Occasionally two fractions were mixed to reach 10 μg of
protein. After transfer, the nitrocellulose sheets were soaked in
primary antibodies (1:1,000) and suitable peroxidase-conjugated
antibodies. Blots were developed using ECL Plus. For semiquantitative
estimation of the difference in Cav3 levels between NM and DM, the
Cav3-rich membrane fractions were pooled, diluted three-fold with
MES-buffered saline, centrifuged 15 min at 14,000×g, and Western
blotted. The intensity of ECL signals was measured with a Typhoon
9410 Imager (AmershamBiosciences) and aMicrom image processing
MIP 4.5 software (CID, Barcelona, Spain). In each Western blot assay,
one normal and one dystrophic sample were compared, assigning a
value of 1 to the total signal intensity of the raft fraction of normal
muscle. Statistical analysis was performed by the Student's t-test.
2.4. Immunolabelling of Cav3 in muscle sections
Frozen muscle sections (0.4-0.5 mm thick) were ﬁxed in buffered
4% paraformaldehyde, washed three times with a saline phosphate
buffer, incubated with 0.1% Triton X-100 in the above buffer for 1 h,
and washed again. After blocking with 3% bovine serum albumin in
phosphate buffer, muscle sections were soaked overnight in anti-Cav3
antibodies (1:300) washed and incubated with Alexa Fluor 488 goat
anti-mouse IgG (1:1,000). The slides were observed under a Leica TCS
SP2 AOBS confocal module equipped with an HCX PLAN APO-CS
40.0×1.25 oil immersion lens. Confocal images were obtained by
excitation with an Ar laser at 488 nm and an emission of 519 nm for
Alexa Fluor 488. For image analysis, the mean integrated optical
density of 10 microscopic ﬁelds of NM and DM sections was recorded
using a Microm image processing MIP 4.5 software. Statistical
differences between normal and dystrophic muscle sections in Cav3
labelling were examined by the Mann-Whitney rank sum test.
2.5. Enzymatic assays
eNT activity was assayed with 1 mM AMP and the released
phosphate was determined with a mixture of ammonium molibdate
and Fiske-Subbarow reagent [27]. One unit of eNT activity (U) is the
amount of enzyme that hydrolyzes one nmol of AMP per min at 37 °C.
Cholinesterase (ChE) activity in the gradient fractions was assayed
by the Ellman method [11]; AChE with 1 mM acetylthiocholine plus
50 µM Iso-OMPA and BuChE with 1 mM butyrylthiocholine plus
10 µM BW284c51. Inhibition of BuChE activity by Triton X-100 was
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given in arbitrary units, one unit referring to an increase of 0.001
absorbance units per microliter of sample, and per minute. In
sedimentation analysis, ChE activity was normalized for the volume
of sample loaded onto the gradient. Activity values for NM and DM
were compared by the Mann-Whitney rank sum test.
2.6. Identiﬁcation of AChE forms located at lipid rafts
Fractions with lipid rafts were pooled and centrifuged. The pellet
was extracted with a Tris-Triton X-100 buffer (150 mM NaCl, 5 mM
EDTA, 60 mM octyl-glucoside, 1% Triton X-100 in 10 mM Tris-HCl, pH
8.0). Fractions with Triton-soluble membranes were also pooled and
dialyzed in MBS for sucrose removal. AChE and BuChE forms in the
Triton-resistant and Triton-soluble membranes were resolved by
sedimentation analysis. For this, samples and sedimentation markers
were loaded on 5-20% sucrose gradients containing 0.5% Brij 96. After
centrifugation at 165,000×g, 20 h at 4 °C in a SW41 Beckman rotor,
fractions were collected from the tube bottom, assayed for AChE and
BuChE activities, and sedimentation coefﬁcients of AChE forms were
calculated [28]. The presence of GPI in the raft-bound AChE forms was
tested by incubating samples with PIPLC (3 U/ml), 2 h at 37 °C.
Removal of the hydrophobic domain in GPI-linked AChE was assessed
by sedimentation analysis.
2.7. Lectin interaction assays
Lectin binding assays were used for testing possible differences
between oligoglycans linked to homologous AChE forms in erythro-
cyte and lipid rafts of muscle. For this, lipid raft extracts (0.5 ml) were
mixed with the same volume of Sepharose 4B (control) and of
agarose-linked Lens culinaris agglutinin, wheat germ agglutinin and
Ricinus communis agglutinin. After overnight incubation, agarose-
bound AChE was removed and unbound AChE activity was quantiﬁed
by sedimentation analysis [11].
2.8. Real time PCR for measuring the relative content of ChE mRNAs
Possible changes in the content of ChE mRNAs as the result of
muscular dystrophywere examined by RT-PCR, using ﬁve NM and ﬁve
DM samples. Details of RNA extraction frommuscle and of assessment
of its higher amount in DM than NM have been reported elsewhere
[29]. For reverse transcription, 5 µg of total RNA (pre-treated with
DNase I) was heated 10 min at 70 °C and cooled. A mixture of buffer,
dNTPs, dithiothreitol, random primers and ribonuclease inhibitor was
added, and all heated 2 min at 42 °C. Then, 200 units of MMLV reverse
transcriptase were added and cDNA synthesis performed at 42 °C for
50 min in a volume of 20 μl. Finally, cDNA samples were heated at
70 °C for 15 min.
PCR primers (Fig. 1) were designed for amplifying speciﬁc cDNAs
that contained one of the ﬁve alternative exons (E1a, E1b, E1c, E1d
and E1e) at the 5’ region of the ACHE gene [8,9], as well as for
amplifying the three cDNAs arising from the 3’ spliced AChE mRNAs
(R, H and T), and PRiMA, BuChE and β-actin mRNAs. For ampliﬁcation
we used an Applied Biosystems 7500 Real-time PCR machine and a
MicroAmp Optical 96-well Reaction Plate with 25 µl of reaction
volume, containing 2 µl of variable dilutions of cDNA, 0.2 µM of
speciﬁc primers and a PCR Master Mix from Applied Biosystems.
Reactions included a ﬁrst step of 10 min at 95 °C, and 45 cycles of 15 s
at 95 °C and 60 s at 60 °C. A ﬁnal dissociating step was added to
analyze the melting curves. The mRNA contents in NM and DM were
compared using the Mann-Whitney rank sum test. PCR products were
resolved in 3% agarose gels and revealed with ethidium bromide.
Their size was calculated with DNA size markers (Sigma) and the
GelPro software.3. Results
3.1. The content of caveolin-3 increases in merosin-deﬁcient mouse muscle
Lipid rafts (Triton-resistant membranes) of muscle were isolated
taking advantage of their insolubility in Triton X-100 and buoyancy in
sucrose gradients. The rafts of NM concentrated in a sharp band (N1)
in fractions 6-8 of the gradient (out of 12; Supplementary Fig. S1A)
and the rafts of DM distributed between a strong band (D1) in
fractions 6-8 and a faint band (D2) in fractions 3-5. Per gram of
muscle, 1.9±1.1 mg of protein was recovered in N1 (n=14), 3.4±
2.3 mg in D1 and 0.19±0.07 mg in D2 (n=12) (Fig. 2A). N1, D1
and D2 contained Cav3 (Fig. 2B), and the double quantity of protein in
D1+D2 (3.6±2.3 mg) compared with N1, along with the nearly 5
times (4.8±1.6, n=6, pb0.001) stronger Western blot signal for
Cav3 in rafts of DM than of NM (Fig. 2C) demonstrated enrichment
of Cav3 and presumably of caveolae in merosin-deﬁcient muscle. The
5-fold increase (5.1±2.6, n=4, pb0.001) in the immunoﬂuorescence
signal for Cav3 in DM sections compared to that in NM slices (Fig. 2D)
lent strong support to the proposal.
3.2. Catalytically active eNT prefers raft membranes and inactive eNT
non-raft membranes
Since the ﬂoating membranes likely consist of Cav3-free and Cav3-
bearing rafts (non-caveolar and caveolar rafts), we next investigated
whether the production of the former was boosted by the deﬁciency
of merosin. For this, we exploited the consideration of eNT activity as a
marker of non-caveolar rafts [22,23]. The fact that both eNT activity
and Cav3 concentrated in the samemembrane fractions of NM (Fig. 3)
supported co-migration of caveolar and non-caveolar rafts, an idea
corroborated by the increased levels of both Cav3 and eNT activity
(2.3±0.6 times, n=5, p=0.038) in the raft-rich fractions of DM
(Fig. 3). Although eNT activity was conﬁned to rafts, Western blots
detected eNT protein in fractions with and without rafts (Fig. 3B).
According to our previous results [29], the bands at 68-72 kDa in the
gel lanes with rafts of NM (rich in eNT activity) should correspond to
active eNT and the triplet at 72-78 kDa in non-raft fractions (lacking
activity) to inactive eNT. Whilst non-catalytic eNT protein was
similarly labelled in non-rafts of NM and DM (Fig. 3) both eNT
activity and eNT protein (blot signal) rose in rafts of DM (2.3±0.6 and
3.4±1.3 times (n=4, p=0.017), respectively), and this conﬁrmed
previous observations concerning the relationship between muscular
dystrophy and the increase of eNT activity in muscle [29].
3.3. Raft microdomains of muscle contain AChE activity
The reports showing interaction ofAChEwithCav1 [21] and theneed
of caveolae for directing rapsyn/nAChR to the sarcolemma [18]
prompted us to explore the presence of ChEs in rafts of muscle.
Although AChE and BuChE activities were mostly measured in non-raft
membranes (Fig. 4A), on the basis of the protein content in the collected
fractions (ChE activity/mg of protein) a signiﬁcant part of AChE activity
(but no BuChE activity at all) was found associated with rafts (Fig. 4A).
The nearly ﬁve-fold (4.6±2.1, n=5, p=0.024) higher AChE activity/
mg protein in rafts of DM than of NM (Fig. 4A) revealed a link between
the density of rafts and the level of raft-bound AChE activity, while the
unequal distribution of AChE activity and Cav3 in the raft-containing
fractions (Fig. 4B) pointed to a preferenceof AChE for non-caveolar rafts,
an idea strongly supported by its enrichment in rafts of Caco-2 cells
(authors’ observations) that do not express Cav1 [30].
3.4. AChE located at lipid rafts of muscle consists of GPI-anchored dimers
The targeting of GPI-anchored proteins to rafts [5], the recent
observation of GPI-anchored AChE in rafts of cultured neuroblastoma/
Fig. 1. Primers used in the PCR assays to quantify AChE, BuChE and PRiMA mRNAs. A) Scheme with the position of the primers. The 3’ parts of p51, p53 and p55, which are
complementary to E4, are only four nucleotides long. B) Primers sequences.
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identiﬁcation of AChE protein (Fig. 4) and enzyme activity (Fig. 5) in
rafts of muscle prompted us to examine whether the raft-bound AChE
consisted of GPI-linked species. Sedimentation analysis revealed that
raft membranes contained only amphiphilic AChE dimers (G2A forms),
whereas non-raft membranes exhibited G1A, G2A and occasionally
hydrophilic tetramers (G4H forms) (Fig. 5). The almost complete
conversion of the raft-associated G2A AChE species into G2H forms with
PIPLC (Supplementary Fig. S3A) allowed us to identify for the ﬁrst
time GPI-anchored AChE dimers in lipid rafts of muscle. As regards
their adsorption to lectins, the raft-residing dimers were fully bound
by Lens culinaris agglutinin and wheat germ agglutinin, and almost
fully bound by Ricinus communis agglutinin (Supplementary Fig. S3B).This lectin interaction pattern differed from the one displayed by
AChE dimers of sarcoplasmic reticulum [11] and blood cells [14].
3.5. The levels of AChE and BuChE mRNAs are unaffected and that of
PRiMA mRNA decreases in merosin-deﬁcient muscle
A comparison of the content of AChE and BuChEmRNAs in NM and
DM could improve current understanding on the capacity of muscle
for expressing the range of AChE mRNAs that differ in the choice of
transcription initiation sites and alternative splicing (Figs. 1 and 6). In
addition, the study might unveil possible differences between normal
and dystrophic muscle in the splicing pattern of the ACHE gene. Fig. 6
shows that the AChE mRNAs with E1c and E1e exons prevail over
Fig. 2. Triton X-100-resistant lipid rafts were isolated from normal muscle (NM) and dystrophic muscle (DM) by isopycnic centrifugation. (A) Protein content in the gradient
fractions. The inset shows the protein amount in the raft-rich fractions at an ampliﬁed scale. (B) Protein blots for Cav3 in the fractions, with 10 µg of protein per lane. (C) Relative
content of Cav3 in lipid rafts. The membrane fractions rich in Cav3 were pooled, and the membranes were sedimented and subjected to Western blot. The total amount of protein
loaded per lane is indicated. Please note that 5 µg of NM sample gave a much lower signal than 2 µg of DM sample. Quantitative analysis showed a ﬁve-fold higher content of Cav3 in
rafts of DM than of NM. (D) Immunoﬂuorescence analysis of normal and dystrophic muscle sections showing a 5-fold stronger labelling of Cav3 in merosin-deﬁcient muscle
(pb0.001). Scale bar=150 μm.
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mRNA over the AChE-R and AChE-H mRNAs. It is worth noting that
the E1e-containing mRNA encodes for an AChE subunit with an N-
terminal extension which potentially allows membrane anchorage.
The levels of BuChE and PRiMAmRNAs exceeded those of AChE-R and
AChE-H mRNAs. The lack of differences in the content of AChE and
BuChE mRNAs between NM and DM contrasted with the sixteen-fold
lower level of the PRiMA mRNA in merosin-deﬁcient than in normal
muscle (210 vs. 3500 copies; n=5, pb0.001; Fig. 6), which dem-
onstrated for the ﬁrst time down-regulation of PRiMA in dystrophic
muscle.
4. Discussion
4.1. The content of caveolin-3 increases in merosin-deﬁcient mouse
muscle
The insolubility of lipid rafts in Triton X-100 and their ﬂotation in
sucrose gradients allowed us to isolate the lipid raft populations. They
appeared as a single band (N1) in preparations of normal muscle and
two bands (D1 and D2) in those of merosin-deﬁcient dystrophic
muscle (Supplementary Fig. S1). The almost 5-fold higher Westernblot signal for Cav3 in D1+D2 than N1 (Fig. 2C) and stronger Cav3
labelling in Lama 2dy mouse muscle sections (Fig. 2D) supported a
relationship between the deﬁciency of merosin and, therefore, of
laminin-2 in muscle and the up-regulation of Cav3. In addition, the
increase of Cav3 in merosin-deﬁcient muscle (this report) and
dystrophin-deﬁcient muscle [17,32] links muscular dystrophy with
caveolae expansion and agrees with the dystrophic phenotype of the
Cav3 over-expressing mouse [33].
The high level of cholesterol in dystrophic muscle [34], its
inﬂuence on the size and shape of rafts [17] and its activating effect
on Cav expression [35] might explain the recovery of two raft
populations (D1 and D2) in merosin-deﬁcient muscle and its
increased content of Cav3. The role that Cav3 fulﬁls in myoblast
fusion, the lower density of rafts as myoﬁbres mature [36], the
muscular damage produced by statins, that lower cholesterol level
and, therefore, the caveolae population [37], and our data pointing to
an expansion of caveolar and non-caveolar (see below) rafts in DM all
agree with the postulated impairment of myoﬁber differentiation as a
leading factor for muscular dystrophy [38]. In addition, the high level
of calcium in dystrophic muscle [39] and its activating effect on
caveolin synthesis [40] make the deregulation of calcium homeostasis
a probable cause for the excess of Cav3 in dystrophic muscle.
Fig. 3. Distribution of eNT activity and eNT protein in raft and non-raft membranes of NM and DM. (A) eNT activity in fractions from the sucrose gradient. Note the greater eNT
activity in DM than in NM, the conﬁnement of the activity to rafts, and the higher speciﬁc eNT activity in raft membranes of dystrophic muscle. Plots show activity per milligram of
protein (speciﬁc activity) and per volume. (B)Western blot with eNT protein in gradient fractions, with 10 µg of protein per lane. Note the difference in intensity and size of bands of
eNT protein in raft and non-raft fractions.
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non-caveolar rafts in merosin-deﬁcient muscle
The resistance of eNT activity to detergent extraction [27], its
absence fromcaveolae [41], and thehigher eNT activity/mgof protein in
rafts (Fig. 3A) thanwholemuscle [15] all agreewith the consideration of
eNT activity as a marker of non-caveolar rafts [22]. The rise of Cav3 and
eNT activity in the Triton-resistant membranes of DM supports
expansion of caveolar and non-caveolar rafts, and the raft localization
of active eNT (that converts AMP into adenosine) as well as adenosine
receptors and adenosine deaminase [42] gives functional signiﬁcance to
the increase of eNT activity in dystrophic muscle [15].
4.3. Lipid rafts of muscle contains GPI-anchored dimers
AChE of muscle has been thoroughly studied because this enzyme
is required for the correct coupling of excitation with contraction. The
overwhelming amount and functional relevance in muscle of the
AChE-T subunit (compared with AChE-H and AChE-R subunits) have
boosted research onto regulatory aspects of the AChE-T mRNA
expression, translation, oligomerisation of AChE-T subunits, assembly
with non-catalytic (structural) subunits, and transport of oligomers to
speciﬁc stores of muscle [10]. In fast muscle, AChE occurs as A12 forms
made of T subunits at the NMJ and as PRiMA-bearing tetramers (G4A
species) at the sarcolemma, whereas in slow ﬁbres AChE appears as
G1, G4A, A4 and A8 forms at synaptic and non-synaptic areas [13,43].
As regards the translation of themuscle AChE-HmRNA, despite the
long time elapsed since its observation [44], the lack of information on
AChE-H protein challenged the capacity of muscle for translating the
AChE-HmRNA. The identiﬁcation of G2A AChE species in rafts of muscleand their conversion into G2H forms with PIPLC (Supplementary
Fig. S2A) demonstrate for the ﬁrst time that muscle can translate the
AChE-H mRNA and the existence of an as yet undetected pool of raft-
residing AChE-H protein in the form of GPI-anchored dimers. This
pool of dimers had probably remained unnoticed in whole muscle
studies owing to the greater quantity of AChE-T than of AChE-H
tailored molecules. The concentration in rafts of the latter permitted
their identiﬁcation.
The raft-residing AChE-H dimers were fully bound by Lens culinaris
agglutinin and wheat germ agglutinin, and almost totally by Ricinus
communis agglutinin (Suppl. Fig. S2B), this lectin binding pattern
differing substantially from that displayed by AChE dimers of
sarcoplasmic reticulum [11] and blood cells [14]. Thus, along with
the report showing AChE in caveolin-free membranes of erythrocytes
[45], the differences between the AChE dimers in rafts of muscle and
in erythrocytes in PIPLC sensitivity and extent of lectin binding (Suppl.
Fig. S2) [14] ruled out a possible erythrocytic origin of the raft-bound
AChE. Finally, the lower binding extent of Ricinus communis agglutinin
with the AChE dimers of nerves [3] than of rafts (Suppl. Fig. S3B)
discarded their possible neural origin.
The abundance in whole muscle and internal stores of asymmetric
and tetrameric AChE-T [11], which are lacking in rafts (Fig. 5), and the
rise of AChE activity (as dimers) in rafts of DM suggested package of
particular subsets of AChE forms in distinct transport vesicles for their
delivery to particular subcellular compartments of the myoﬁbre.
4.4. 5’-Alternative AChE mRNAs
Our RT-PCR results demonstrate that mouse muscle expresses all
ﬁve 5’ alternative AChE transcripts described to date and the three
Fig. 4. Identiﬁcation of AChE in lipid rafts. (A) Distribution of AChE and BuChE activities in gradient fractions showing high speciﬁc AChE activity in lipid rafts and absence of BuChE
activity from rafts. (B) Western blots with different banding patterns of AChE in raft and non-raft fractions (10 µg protein/lane). The strong labelling of AChE in raft fractions of DM
agrees with their higher AChE activity.
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mRNAs with exons E1c and E1e prevailed over those with exons E1d,
E1b and E1a in mouse muscle (this work) and brain [9], and this
prevalence allowed us to report for the ﬁrst time the capacity of
muscle and brain to express AChE transcripts containing the E1e
exon which encodes the N-terminal extension. Our mRNAs dataagree with those of the Soreq's group, who also observed abundant
E1c-containing transcripts in most mouse tissues, including muscle,
and undetectable or very low levels of mRNAs with E1d, E1b and E1a
in muscle [46]. The expression level of E1e mRNAs in mouse organs
was not analyzed in that work. Nevertheless, the substantial amount
of E1e mRNAs in mouse muscle with respect to the total AChE
Fig. 5. Sedimentation proﬁles with cholinesterase forms in raft and non-raft fractions of NM and DM. Raft membranes are devoid of BuChE activity. Sucrose gradients contained 0.5%
Brij 96. C and P denote catalase and alkaline phosphatase.
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of the homologous 5’-spliced mRNA variant [46]. Finally, the
increasing abundance of AChE-H, AChE-R and AChE-T mRNAs in
mouse muscle (Fig. 6) also coincides with previous observations
[46].
The identiﬁcation in mouse muscle (this work) and brain [9] of
E1e-containing AChE mRNAs that translate into N-terminally extend-
ed AChE subunits and whose extension potentially allows membrane
anchorage [8] points to the production of N-extended AChE variants
in muscle and brain. With respect to muscle, the strong labelling in
lipid rafts of the ∼66-72 kDa double protein band (Fig. 4B) that has
been assigned to human N-extended AChE protein [46] supports its
production in mouse muscle. With respect to brain, it is worth
mentioning the presence in human cortical neurons of both E1e-containing AChE transcripts and N-AChE-T protein and their increased
levels in neurons of patients suffering from Alzheimer disease [47].
This report prompts for an investigation focused on the identiﬁcation
in tissues of the various N-extended AChE proteins and their
functional roles. We shall undertake this study in the near future
using selected cell lines and antibodies against the N-terminal domain
of N-extended AChE.
The prevalence of AChE-T mRNA over AChE-R and AChE-H mRNAs
in muscle (Fig. 6) conﬁrms the need of AChE-T protein for appropriate
functioning, and the lower quantity of AChE-T and PRiMA mRNAs in
mouse muscle (∼9,500 and 3,500 copies/million copies of β-actin
mRNA) (Fig. 6) than brain (35,000 and 8,000 copies) [9] agrees with
the functional importance of G4A AChE (the PRiMA-linked tetramers)
for brain. The identiﬁcation of BuChE and PRiMA mRNAs in muscle
Fig. 6. Expression of AChE, BuChE and PRiMA mRNAs. (A) Agarose gels showing the RT-PCR products for the 5’ (E1a, E1b, E1c, E1d and E1e) and 3’ (AChE-T, AChE-H and AChE-R)
alternative mRNAs, as well as those for the BuChE and PRiMAmRNAs. (B) Histogramwith levels of the mRNAs in NM and DM. The relative amounts of mRNAs are given as number of
copies per million copies of the β-actin mRNA. Mean values of ﬁve NM and ﬁve DM samples. (*) Note the 16-fold lower level of the PRiMAmRNA inmerosin-deﬁcient muscle than in
normal muscle (pb0.001).
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support neuromuscular transmission in AChE-null mice, which lack
the homologous AChE forms [48].
4.5. The PRiMA subunit is down-regulated in merosin deﬁcient muscle
The comparable amounts of AChE and BuChE mRNAs in healthy
and merosin-deﬁcient muscle contrasted with the sixteen-fold lower
level of the PRiMA mRNA in merosin-deﬁcient than in normal muscle
(Fig. 6). This down-regulation of PRiMA would explain the reported
decrease of G4A AChE and BuChE in dystrophin-deﬁcient and merosin-
deﬁcient dystrophic muscle [11,49]. The role of PRiMA in converting
G4 AChE into G4A forms, and, hence, in attenuating the synthesis of
asymmetric AChE [43], might account for the similar levels of G4A AChE
in dystrophic fast-twitch and normal slow-twitch muscles, that are
lower than in healthy fast-twitch muscle [50]. Down-regulation of
PRiMA may be inherent to dystrophy; it may arise from early
myogenin synthesis [51] and its suppressive action on PRiMA [43].
The need of PRiMA for targeting G4A AChE to the cell membrane in
differentiating neurons [52] could mean that the down-regulation of
PRiMA is responsible for the loss of G4A AChE and BuChE in merosin-
deﬁcient nerves [3], but further work is needed to conﬁrm this.
4.6. Possible signiﬁcance of AChE located in muscle lipid rafts
The role of lipid rafts in targeting nAChR [53] and our data
revealing raft-bound AChE highlight the importance of rafts in
targeting cholinergic proteins. The higher content of raft-conﬁnedAChE activity (in the form of AChE-H dimers) in Lama2dy muscle
compared to wild typemuscle (Figs. 4, 5, and Supp. Fig. S3A) contrasts
with their similar levels of AChE-HmRNA (Fig. 6). This increased level
of raft-bound AChE activity may arise from: 1) release of mRNA-
blocking micro-RNA; 2) faster translation; 3) improved posttransla-
tional maturation, including folding of AChE-H polypeptides, efﬁcien-
cy of GPI addition, conversion of catalytically incompetent into
catalytic molecules, evasion from proteolysis, dimerization and exit
to the Golgi [10]; and 4) favourable incorporation therein of the
glypiated AChE in rafts and further targeting to the sarcolemma.
Elucidation of these possible reasons deserves further investigation.
Concerning the functional signiﬁcance of raft-bound AChE, the
presence of muscarinic receptors (mAChR) in lipid rafts of muscle
[54,55] supports a role for raft-bound AChE in cholinergic responses.
The increased level of AChE activity in rafts of dystrophic muscle may
contribute to the pathology by lowering the availability of acetylcho-
line. In addition, given 1) the non-enzymatic actions of AChE [10]; 2)
its capacity to interact with laminin [19,20,56]; and 3) the similar
structural motifs in AChE, syndecans, perlecans and other heparin
sulfate proteoglycans [19], it is conceivable that the raft-bound AChE
can contribute to the stabilization of the basal lamina of muscle.5. Conclusions
The results reported herein demonstrate for the ﬁrst time that the
deﬁciency of merosin produces an increase in the content of Cav3 and
of raft-bound eNT activity in muscle. These observations, besides the
increased density of caveolae in dystrophin-deﬁcient muscle [16,17],
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trophic phenotype causes an increase in the population of caveolar
and non-caveolar lipid rafts. The results are compatible with the
notion of overproduction of lipid rafts in the damaged myoﬁbre for
speeding up protein transport to the sarcolemma and activate repair.
The identiﬁcation of GPI-anchored AChE dimers in rafts of muscle
justiﬁes its content of AChE-H mRNAs and supports a role for rafts in
delivering AChE toward the sarcolemma. Finally, the fact that PRiMA
expression is down-regulated in merosin-deﬁcient muscle would
explain the loss of the physiologically relevant PRiMA-linked AChE
and BuChE tetramers in dystrophic muscle.
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